Ecdysone receptor ligand-binding domain (EcR-LBD)

The Ecdysone receptor (EcR) ligand-binding domain is the central regulatory component of the RheoSwitch Therapeutic System (RTS), a proprietary inducible gene expression platform used in advanced gene therapies (NIH, 1.2.1, 1.2.3). In this system, the EcR domain—typically derived from the spruce budworm, Choristoneura fumiferana—is fused to a DNA-binding domain such as Gal4 to create a chimeric, ligand-inducible transcription factor (PNAS, 1.4.1; NIH, 1.4.2). This fusion protein remains transcriptionally inactive in the absence of its specific small-molecule inducer, such as Veledimex (RG-115819). Upon oral administration and subsequent binding of the ligand, the EcR domain undergoes a conformational change that promotes dimerization with a partner protein (often a modified Retinoid X Receptor) and binding to Gal4-responsive promoters to drive the expression of a therapeutic gene, most commonly Interleukin-12 (IL-12) (NIH, 1.3.2, 1.3.4). This technology allows for precise, dose-dependent control over the timing and magnitude of protein production within the patient, which is particularly valuable for managing the toxicity of potent cytokines in the treatment of solid tumors like glioblastoma (ASCO, 1.2.4; NIH, 1.3.1).

Other names

RheoSwitchEcREcdysone receptorGal4-EcR fusion proteinLigand-inducible transcription factorChoristoneura fumiferana ecdysone receptor

Veledimex acts as a small-molecule activator that binds to the ecdysone receptor ligand-binding domain, inducing a conformational change that enables the Gal4-EcR fusion protein to dimerize with a co-activation partner (typically a modified RXR) and bind to specific DNA response elements, thereby initiating the transcription of a linked therapeutic transgene.